Evidence map›Paper›PMID 35542043›Full record

ReviewChemNanoMat : chemistry of nanomaterials for energy, biology and more2022

Nanotechnology Toolkit for Combating COVID-19 and Beyond.

Giredhar Muthiah, Ankita Sarkar, Shounak Roy, Prem Singh, Praveen Kumar, Keshav Bhardwaj, Amit Jaiswal

Open access · greenAbstract readReview
In one paragraph

Review in ChemNanoMat : chemistry of nanomaterials for energy, biology and more, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Nanotechnology Toolkit for Combating COVID-19 and Beyond.ChemNanoMat : chemistry of nanomaterials for energy, biology and more · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Giredhar MuthiahSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Ankita SarkarSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Shounak RoySchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Prem SinghSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Praveen KumarSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Keshav BhardwajSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.
Amit JaiswalSchool of Basic Sciences Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India.ORCID 0000-0002-9748-0404
Indian Institute of Technology Mandi · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak of SARS-CoV-2 is unlikely to be contained anytime soon with conventional medical technology. This beckons an urgent demand for novel and innovative interventions in clinical protocols, diagnostics, and therapeutics; to manage the current "disease X" and to be poised to counter its successor of like nature if one were to ever arise. To meet such a demand requires more attention to research on the viral-host interactions and on developing expeditious solutions, the kinds of which seem to spring from promising domains such as nanotechnology. Inducing activity at scales comparable to the viruses themselves, nanotechnology-based preventive measures, diagnostic tools and therapeutics for COVID-19 have been rapidly growing during the pandemic. This review covers the recent and promising nanomedicine-based solutions relating to COVID-19 and how some of these are possibly applicable to a wider range of viruses and pathogens. We also discuss the type, composition, and utility of nanostructures which play various roles specifically under prevention, diagnosis, and therapy. Further, we have highlighted the adoption and commercialization of some the solutions by large and small corporations alike, as well as providing herewith an exhaustive list on nanovaccines.

Indexed as

COVID-19NanomaterialsPPESARS-Cov-2Vaccine

Identifiers

PMID35542043
PMCPMC9074423
OpenAlexW4210723640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.